Bidirectional Crosstalk Between Cancer Stem Cells and Immune Cell Subsets.
Cell Communication
/ immunology
Cell Dedifferentiation
/ immunology
Humans
Immunomodulation
Immunotherapy
/ methods
Macrophages
/ immunology
Myeloid-Derived Suppressor Cells
/ immunology
Neoplastic Stem Cells
/ immunology
Phenotype
T-Lymphocytes
/ immunology
Tumor Escape
Tumor Microenvironment
/ immunology
T cells
cancer stem cells
macrophages
myeloid-derived suppressor cells
tumor microenvironment
Journal
Frontiers in immunology
ISSN: 1664-3224
Titre abrégé: Front Immunol
Pays: Switzerland
ID NLM: 101560960
Informations de publication
Date de publication:
2020
2020
Historique:
received:
26
11
2019
accepted:
20
01
2020
entrez:
3
3
2020
pubmed:
3
3
2020
medline:
9
3
2021
Statut:
epublish
Résumé
Cancer stem cells (CSCs), also known as tumor-initiating cells, are characterized by an increased capacity for self-renewal, multipotency, and tumor initiation. While CSCs represent only a small proportion of the tumor mass, they significantly account for metastatic dissemination and tumor recurrence, thus making them attractive targets for therapy. Due to their ability to sustain in dormancy, chemo- and radiotherapy often fail to eliminate cancer cells with stemness properties. Recent advances in the understanding of the tumor microenvironment (TME) illustrated the importance of the immune contexture, determining the response to therapy and clinical outcome of patients. In this context, CSCs exhibit special properties to escape the recognition by innate and adaptive immunity and shape the TME into an immunosuppressive, pro-tumorigenic landscape. As CSCs sculpt the immune contexture, the phenotype and functional properties of the tumor-infiltrating immune cells in turn influence the differentiation and phenotype of tumor cells. In this review, we summarize recent studies investigating main immunomodulatory properties of CSCs and their underlying molecular mechanisms as well as the impact of immune cells on cancer cells with stemness properties. A deeper understanding of this bidirectional crosstalk shaping the immunological landscape and determining therapeutic responses will facilitate the improvement of current treatment modalities and the design of innovative strategies to precisely target CSCs.
Identifiants
pubmed: 32117287
doi: 10.3389/fimmu.2020.00140
pmc: PMC7013084
doi:
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
140Informations de copyright
Copyright © 2020 Müller, Tunger, Plesca, Wehner, Temme, Westphal, Meier, Bachmann and Schmitz.
Références
Cell Signal. 2013 Apr;25(4):961-9
pubmed: 23333246
Cancer Res. 2014 May 15;74(10):2698-709
pubmed: 24638980
Oncoimmunology. 2018 Aug 6;7(10):e1478647
pubmed: 30288344
Arch Pharm Res. 2016 Nov;39(11):1588-1596
pubmed: 27562774
Biomed Res Int. 2015;2015:635745
pubmed: 26649310
Int J Cancer. 2013 May 1;132(9):1977-85
pubmed: 23034889
FASEB J. 2013 Jan;27(1):13-24
pubmed: 23024375
Cancer Res. 2019 Apr 1;79(7):1507-1519
pubmed: 30692216
Neuro Oncol. 2010 Nov;12(11):1113-25
pubmed: 20667896
Stem Cells. 2017 Dec;35(12):2351-2365
pubmed: 29044882
J Cell Mol Med. 2013 Nov;17(11):1415-21
pubmed: 24283947
Genes Dev. 2017 Feb 1;31(3):247-259
pubmed: 28223311
ScientificWorldJournal. 2011;11:2391-402
pubmed: 22194670
Cancer Res. 2009 Sep 15;69(18):7243-51
pubmed: 19738068
Mol Cancer Ther. 2010 Jan;9(1):67-78
pubmed: 20053772
Genes Cells. 2016 Mar;21(3):241-51
pubmed: 26805963
J Exp Clin Cancer Res. 2019 Jul 5;38(1):289
pubmed: 31277685
Clin Cancer Res. 2015 May 15;21(10):2325-37
pubmed: 25717063
Free Radic Biol Med. 2014 Feb;67:41-50
pubmed: 24145120
Cancer Sci. 2019 May;110(5):1564-1572
pubmed: 30861269
Hepatology. 2014 Jul;60(1):179-91
pubmed: 24523067
Mediators Inflamm. 2016;2016:9012369
pubmed: 26980947
J Clin Oncol. 2015 Jun 10;33(17):1974-82
pubmed: 25605845
Anticancer Res. 2012 Sep;32(9):3847-53
pubmed: 22993328
Oncology. 2016;90(5):267-72
pubmed: 27077749
Nat Cell Biol. 2015 Feb;17(2):170-82
pubmed: 25580734
Nat Cell Biol. 2014 Nov;16(11):1105-17
pubmed: 25266422
Nat Med. 2017 Oct 6;23(10):1124-1134
pubmed: 28985214
Cancer Lett. 2012 May 28;318(2):173-9
pubmed: 22198207
Proc Natl Acad Sci U S A. 2011 Jan 25;108(4):1397-402
pubmed: 21220315
Nat Rev Immunol. 2010 Jul;10(7):479-89
pubmed: 20559326
PLoS One. 2015 Aug 18;10(8):e0135528
pubmed: 26284927
Nat Rev Immunol. 2010 Jul;10(7):490-500
pubmed: 20559327
Head Neck. 2011 Feb;33(2):208-15
pubmed: 20848440
J Exp Med. 2012 Sep 24;209(10):1883-99
pubmed: 22945919
Annu Rev Physiol. 2017 Feb 10;79:541-566
pubmed: 27813830
Nat Rev Clin Oncol. 2017 Dec;14(12):717-734
pubmed: 28741618
Nat Rev Cancer. 2016 Aug 23;16(9):566-81
pubmed: 27550819
Cancer J. 2018 Jul/Aug;24(4):193-204
pubmed: 30119083
J Immunol. 2019 Aug 1;203(3):585-592
pubmed: 31332079
Cell Res. 2009 Feb;19(2):156-72
pubmed: 19153598
Expert Opin Biol Ther. 2020 Jan;20(1):5-8
pubmed: 31663384
Cell Oncol (Dordr). 2017 Oct;40(5):471-482
pubmed: 28643230
Int J Biol Sci. 2012;8(9):1248-53
pubmed: 23136553
J Ovarian Res. 2014 Feb 08;7:19
pubmed: 24507759
Nat Med. 2018 May;24(5):541-550
pubmed: 29686425
Springerplus. 2013 Jul 04;2(1):301
pubmed: 23888272
J Cell Physiol. 2017 Aug;232(8):2008-2018
pubmed: 28019667
Cancer Immunol Immunother. 2014 May;63(5):513-28
pubmed: 24652403
Cancer Res. 2014 Oct 15;74(20):5746-57
pubmed: 25164008
Protein Cell. 2018 Jun;9(6):516-526
pubmed: 28290053
Nat Commun. 2017 Jun 01;8:15080
pubmed: 28569747
J Immunol. 2015 Oct 15;195(8):4010-9
pubmed: 26363055
Pancreas. 2015 Jul;44(5):756-63
pubmed: 25931255
Biochem Biophys Res Commun. 2007 Aug 31;360(3):553-9
pubmed: 17618600
Cancer Immunol Res. 2017 Jan;5(1):3-8
pubmed: 28052991
Clin Cancer Res. 2010 Feb 1;16(3):800-13
pubmed: 20103663
Cancer Res. 2006 Aug 15;66(16):7843-8
pubmed: 16912155
Trends Immunol. 2002 Nov;23(11):549-55
pubmed: 12401408
Mol Med Rep. 2015 Jun;11(6):4685-93
pubmed: 25672286
Clin Exp Immunol. 2018 Jan;191(1):60-73
pubmed: 28868628
Gastroenterology. 2018 Jul;155(1):210-223.e3
pubmed: 29604293
Nat Rev Cancer. 2015 Jun;15(6):361-70
pubmed: 25998715
Cancer Lett. 2018 Aug 1;428:117-126
pubmed: 29653268
Nature. 2019 Aug;572(7768):254-259
pubmed: 31316209
J Neuroimmunol. 2011 Mar;232(1-2):75-82
pubmed: 21056915
Cancer Immunol Immunother. 2014 Jul;63(7):721-35
pubmed: 24711084
Oncogene. 2017 Mar 2;36(9):1256-1264
pubmed: 27524415
Immunity. 2014 Jul 17;41(1):14-20
pubmed: 25035950
Sci Signal. 2018 May 01;11(528):
pubmed: 29717062
PLoS One. 2010 Jul 16;5(7):e11590
pubmed: 20661281
Clin Exp Pharmacol Physiol. 2017 May;44(5):602-604
pubmed: 28107571
J Clin Oncol. 2019 Apr 20;37(12):946-953
pubmed: 30811285
J Leukoc Biol. 2011 Jan;89(1):85-91
pubmed: 20952660
Front Immunol. 2017 Apr 21;8:404
pubmed: 28484448
Signal Transduct Target Ther. 2016;1:
pubmed: 28798885
Nature. 1994 Feb 17;367(6464):645-8
pubmed: 7509044
Cancer Res. 2011 Feb 15;71(4):1263-71
pubmed: 21303976
Cancer Lett. 2014 Oct 1;352(2):160-8
pubmed: 24892648
Int J Oncol. 2012 Apr;40(4):1171-9
pubmed: 22134360
Hepatology. 2012 Dec;56(6):2255-67
pubmed: 22898879
J Mol Med (Berl). 2013 Dec;91(12):1355-68
pubmed: 24057813
Proc Natl Acad Sci U S A. 2015 Feb 10;112(6):1839-44
pubmed: 25605917
Oncoimmunology. 2015 Feb 03;4(1):e984539
pubmed: 25949866
Mol Cell Endocrinol. 2012 Sep 5;360(1-2):52-8
pubmed: 21664423
Oncotarget. 2018 Nov 20;9(91):36317-36330
pubmed: 30555631
Biomed Res Int. 2015;2015:314620
pubmed: 26583099
J Immunol. 2014 Jan 1;192(1):523-32
pubmed: 24277698
Cancer Res. 2016 Jun 1;76(11):3156-65
pubmed: 27197152
Breast Cancer Res Treat. 2013 Apr;138(3):657-64
pubmed: 23532539
Proc Natl Acad Sci U S A. 2011 Jul 26;108(30):12425-30
pubmed: 21746895
Int Immunol. 2016 Aug;28(8):401-9
pubmed: 27160722
Cell Stem Cell. 2014 Mar 6;14(3):275-91
pubmed: 24607403
Stem Cells Int. 2019 Jan 13;2019:3904645
pubmed: 30733805
Cell. 2009 Jul 23;138(2):286-99
pubmed: 19632179
Oncogene. 2015 Jan 8;34(2):165-76
pubmed: 24362529
Tumour Biol. 2016 Sep;37(9):11553-11572
pubmed: 27260630
Oncoimmunology. 2014 May 15;3:e28862
pubmed: 25057449
Gastroenterology. 2014 Dec;147(6):1393-404
pubmed: 25181692
BMC Cancer. 2018 Apr 26;18(1):469
pubmed: 29699516
Science. 2018 Mar 23;359(6382):1350-1355
pubmed: 29567705
Am J Pathol. 2011 Apr;178(4):1805-13
pubmed: 21435460
Cancer Res. 2019 Jul 15;79(14):3737-3748
pubmed: 31085700
Clin Cancer Res. 2016 Jul 15;22(14):3571-81
pubmed: 26864211
J Cell Physiol. 2020 Mar;235(3):1903-1914
pubmed: 31332789
Curr Pharm Des. 2006;12(3):387-94
pubmed: 16454752
Immunity. 2013 Sep 19;39(3):611-21
pubmed: 24012420
Oncogene. 2019 Feb;38(6):780-793
pubmed: 30181548
J Exp Med. 2015 Feb 9;212(2):139-48
pubmed: 25601652
Int J Mol Sci. 2019 Jan 23;20(3):
pubmed: 30678134
Cancer Res. 2010 Jan 15;70(2):697-708
pubmed: 20068175